Big pharma interest remains, but the mood is fast turning gloomy.
ApexOnco Front Page
Recent articles
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
The Japanese group licenses sapablursen from Ionis for $280m.
Recent first-in-human trials include Pheast and Auron, plus new targets from Immunocore and Cero.
The companies press on with vilastobart and IMPT-314... up to a point.
The Pfizer-partnered vepdegestrant shows a benefit in ESR1 mutants, but not in all-comers.
J&J decides not to opt in to erzotabart, and Genmab pulls the plug.
The company has caught up with Syndax and overtaken Kura in the first-line menin inhibitor race.
